FDA Brief

Warning letters Drugs

FDA warning letter to

Online Rx Medz

High riskIssued Apr 1Posted Apr 14Center for Drug Evaluation and Research (CDER)

FDA warns Online Rx Medz for selling unapproved, illegally labeled opioids, benzodiazepines, and stimulants online.

What happened

FDA reviewed www.onlinerxmedz.com and found it offering oxycodone 80mg, Xanax 2mg, and Adderall 30mg to U.S. consumers. FDA said the drugs are not FDA-approved and are misbranded (illegally labeled or sold) because they are prescription drugs offered without a prescription and without adequate directions for lay use.

What FDA found

  1. The website sells oxycodone 80mg, Xanax 2mg, and Adderall 30mg as new drugs without FDA-approved applications.

    FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. The drugs are misbranded because their labeling does not give adequate directions for safe lay use.

    FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]
  3. The website offers prescription drugs without requiring a prescription, which misbrands them.

    FD&C Act §§ 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]

What FDA wants

FDA asks the website to stop offering any unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days with corrective steps and documentation.

Who should pay attention

  • online pharmacies and website operators
  • brands or platforms that host or advertise prescription drugs
  • compliance teams monitoring internet drug sales

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk